GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK PLC (LSE:GSK, NYSE:GSK) has been upgraded by Credit Suisse on the assumption that its potential liability for Zantac lawsuits will be much smaller than the US$12bn that has been wiped from its market cap in recent weeks. The Swiss bank swapped its ‘sell' rating for a ‘hold' but trimmed the share price target to 1,430p from 1,630p to reflect a US$5bn base-case of liability costs from Zantac.

GSK 'sell' rating removed as Zantac liabilities expected to be US$5bn

Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?

GSK plc (NYSE:GSK ) Citi's 17th Annual BioPharma Conference September 7, 2022 1:50 PM ET Company Participants Roger Connor - President, Global Vaccines & Global Health Phil Dormitzer - Senior Vice President, Head of Vaccines R&D Conference Call Participants Andrew Baum - Citigroup Andrew Baum Terrific. Well, welcome back.

GSK plc (GSK) Citi's 17th Annual BioPharma Conference Earnings Call Transcript

GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.

GSK's NDA for Daprodustat to be Reviewed by an FDA Panel

Viatris

Verizon

With all the recent market volatility, there is no shortage of stocks that are looking seemingly cheaper when compared to the closing months of 2021. First up, I'm thinking about adding to the recent spin-off Viatris Inc.

September 2022 Stock Considerations

Two major investment banks cut their target prices for GSK PLC (LSE:GSK, NYSE:GSK) as analysts drilled down into the potential fallout from the Zantac litigation and saw the potential for total liabilities for the companies involved of over US$50bn. Morgan Stanley (NYSE:MS) cut its price target to 1,550p from 1,860p, while Deutsche Bank cut to 1,500p from 1,750p.0 Even though the first of the legal cases against companies that sold the heartburn drug was dropped last month, Deutsche analyst Emmanuel Papadakis said a detailed review of the Zantac litigation led the bank to believe GSK and Sanofi are likely to "lose the scientific argument" and consequently are likely to incur liabilities.

GSK targets further cut by investment banks over potential Zantac legal risks

Rolls-Royce Holdings PLC

Tesla

August's most popular shares for retail investors were dominated by apparent bargain hunting, with Rolls-Royce Holdings PLC (LSE:RR.), GSK PLC (LSE:GSK, NYSE:GSK) and Vodafone Group PLC (LSE:VOD) snapped up despite falling between 7% and 19% over the month.

Rolls-Royce, GSK, Tesla, Cineworld and Revolution Beauty top most-bought shares in August

Merck

Morgan Stanley

Novavax

Novartis

Pfizer

Sanofi

It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn medication Zantac.

This Overlooked Danger Could Tank Big Pharma Stocks

New York, New York--(Newsfile Corp. - September 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

AstraZeneca

AstraZeneca PLC (LSE:AZN) has succeeded in stopping a former senior executive from joining rival GSK PLC (LSE:GSK, NYSE:GSK) via an injunction granted by a High Court judge.  Having recently left AstraZeneca after holding several senior positions, Chris Sheldon was due to join GSK on September 1, in charge of developing the group's therapy businesses.

AstraZeneca wins injunction preventing former executive from joining GSK

A little over a year ago is our last coverage on GSK. We looked at implied split in value between GSK's biopharma division and the consumer division, now called Haleon, when it was supposed to split off.

GSK: Haleon Demerger Retrospective

Diageo

Paramount Global

Scotts Miracle-Gro

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

The stock market took a nose dive on August 26th, shedding over 3% in some instances on the overall valuation of the stock market. Diageo yields well above the S&P 500 and is a better yield on average than the majority of high quality stocks.

Dividend Stock Watch List: Lanny's September 2022 Edition

Healthpeak Properties Inc

Medical Properties Trust

These three will pay you well while you wait for their shares to rebound.

3 Dependable Stocks With Dividend Yields Above 5%

GSK was having a turnaround year, with drugs pipeline strong and H1 results impressive. Zantac lawsuits are presenting a significant risk to investing in GSK.

Clouds Are Gathering (Again) For GSK

Alkermes

Editas Medicine

Immunovant Inc

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

Bayer AG

Dr. Reddy's Labs

The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Plaintiff in first Zantac lawsuit set for trial drops case

This month I deployed more cash than last month totaling almost $2,000. People like to talk about crypto volatility but the market in recent months has plenty of examples of wild price swings too.

Recent Stock Purchase August 2022

Los Angeles, California--(Newsfile Corp. - August 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

The withdrawal of the plaintiff in the first lawsuit over GSK's heartburn drug Zantac may not be “as significant as it first appears” for the company's shares, say analysts from RBC Capital Markets.

Zantac lawsuit drop ‘not as significant as it appears' for GSK stock, analysts say

The first of the legal cases against companies that sold the heartburn drug Zantac ended before it started after the plaintiff dropped his case. Joseph Bayer, who brought the action against GSK PLC (LSE:GSK, NYSE:GSK) and Boehringer Ingelheim, was unable to proceed because of health reasons, said Reuters citing his attorney.

GSK: First Zantac case plaintiff drops lawsuit

Los Angeles, California--(Newsfile Corp. - August 16, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Haleon PLC

Johnson & Johnson

Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?

Potential Lawsuits Causing Zantac Manufacturers Heartburn

Los Angeles, California--(Newsfile Corp. - August 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $GSK #GSK--The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

First Bancorp

Fulton Financial

Genuine Parts

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Philip Morris

Schlumberger

TotalEnergies SE

Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.

Bert's July Dividend Income Summary | Dividend Investing 2022

News for GlaxoSmithKline Stock (GSK)